Find a study
Browse recruiting studies near you — free to check, always your choice.
6 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Fibrosis Lessens After Metabolic Surgery
Testing whether metabolic surgery can reduce liver scarring in obesity
📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.
- Crohn's / ulcerative colitis (IBD)💵 May compensate
Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD
Testing whether mirikizumab is safe and works for people with Crohn’s strictures
📍 Digestive & Liver Center of Florida · Orlando, FL · +1 more US site · Get directions →
This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.
- Obesity / overweightHigh blood pressure💵 May compensate
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Testing treatments to lower high pressure in liver veins in people with advanced liver disease and
📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.
- Obesity / overweight💵 May compensate
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
Testing how to choose weight-loss medicines for people with bipolar disorder
📍 Mayo Clinic · Rochester, MN · Get directions →
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in patients with bipolar disorder ages 18-65. The main questions it aims to answer are: * Can the investigators compare the distribution of obesity characteristics (hungry brain, hungry gut, emotional hunger) between bipolar patients and non-bipolar participants (comparing from IRB #24-002375)?
- Obesity / overweight💵 May compensate
Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
Testing metformin for weight gain caused by antipsychotic drugs in adults with intellectual
📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →
People with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD.
- Obesity / overweight💵 May compensate
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Testing whether tirzepatide affects liver fat markers in people with obesity
📍 University of New Mexico Health Sciences Center · Albuquerque, NM · Get directions →
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity.